During a Science and Innovation Product Theater, sponsored by Amgen, Seth J. Baum, MD, FAAC, FACPM, FAHA, FNLA, FASPC, president of the American Society for Preventive Cardiology, explained the significance of evolocumab's expanded indication, which makes it no longer mandatory for patients to try statins first.